Is the US prepared to deal with another pandemic or widespread health crisis?

The US is better prepared in several key areas than it was before COVID-19 but is not fully ready for another major pandemic or widespread health crisis, according to government assessments, independent commissions, GAO reports, WHO evaluations, and public health analyses. Significant progress has been made in stockpiles, surveillance, manufacturing capacity, and organizational structures, yet persistent gaps in funding sustainability, coordination, workforce, state-level readiness, public trust, and leadership leave vulnerabilities. Experts and bipartisan groups emphasize that biological threats (natural, accidental, or deliberate) are growing, and “immediate action” is still needed.[1]

Key Improvements Since COVID-19

•Strategic National Stockpile (SNS): The SNS has been substantially replenished. It now holds roughly 70 times the pre-pandemic number of N95 respirators, 34 times the gloves, 50 times the isolation gowns, and 10 times the ventilators. It has supported responses to H5N1, mpox, and other threats, with ongoing sustainment, quality assurance, and shelf-life extension efforts.[2]

•Surveillance and data systems: Electronic case reporting expanded dramatically—from fewer than 200 healthcare facilities in 2020 to over 45,000–48,000 by 2024. Syndromic surveillance covers most hospital emergency departments, and capabilities for near real-time monitoring have improved. CDC has invested in forecasting, modeling, and “warm base” clinical lab partnerships for rapid test development/deployment.[2]

•Organizational and policy advances: The Office of Pandemic Preparedness and Response Policy (OPPR) was established in 2023 as a permanent White House office for coordination. Updated National Biodefense Strategy, Global Health Security Strategy (2024), and American Pandemic Preparedness Plan elements exist. Medical countermeasure (MCM) development, domestic manufacturing incentives (via Defense Production Act and other tools), and dual-use research oversight have advanced. Vaccine platforms (e.g., mRNA) and therapeutics pipelines are stronger.[2]

•International and evaluation metrics: The US underwent a Joint External Evaluation (JEE) of International Health Regulations core capacities in September 2024 (using the post-COVID tool). It scores highly (often 4–5 out of 5 for demonstrated/sustainable capacity) in many technical areas such as immunization, laboratory systems, surveillance, health emergency management, and points of entry, though with recommendations for improvement.[3]

•Lessons incorporation: CDC reorganized aspects of readiness/response, expanded quality controls for testing, and improved partnerships. GAO and others note successes in leveraging existing infrastructure (e.g., pharmacies for vaccines) and some flexibilities (telehealth).

Biden-Harris administration roadmaps (as of early 2025) highlighted these as transforming preparedness, including equitable response elements and global contributions (e.g., Pandemic Fund, vaccine sharing).[2]

Persistent Gaps and Challenges

•Unimplemented recommendations and systemic issues: As of mid-2024, GAO had made hundreds of COVID-related recommendations (428+), with over 200 still open. High-risk areas include HHS leadership/coordination of public health emergencies. Lessons span planning (roles/responsibilities, surge capacity), collaboration, clear communication, data sharing, program integrity, and leveraging infrastructure. Gaps in biodefense enterprise implementation of the National Biodefense Strategy persist.[4]

•State and local variability: Trust for America’s Health (TFAH) Ready or Not reports (e.g., 2025) place many states in middle or low performance tiers for emergency preparedness (e.g., ~21 high, 16 middle, 13 low in one recent assessment). Issues include inconsistent public health funding (some states cut it post-COVID supplemental expiration), low flu vaccination rates (~44–47%, far below 70% goals), workforce challenges, avoidable mortality disparities, and paid sick leave access. Hospital and healthcare system surge capacity remains uneven.[5]

•Funding and sustainability: Public health and preparedness funding has been unstable. COVID supplemental funds expired; core programs like Public Health Emergency Preparedness (PHEP) and Hospital Preparedness face pressures or proposed cuts in recent budgets. MCM development (via BARDA/SNS) often relies on emergency appropriations rather than sustained baselines. Recent analyses note declines or flat funding in biodefense categories amid competing priorities, workforce attrition, and proposed reductions (e.g., to CDC programs or global health security elements). Professional judgment budgets highlight multi-billion-dollar gaps for full MCM readiness against CBRN and emerging threats.[6]

•Leadership, coordination, and detection: Multiple agencies share biodefense roles without always clear White House-level quarterbacking or authority. Federal-state tensions and ambiguities reappeared in responses (e.g., H5N1 bird flu in cattle, with monitoring/testing challenges due to personnel/funding shortages and agriculture-health coordination). BioWatch (airborne pathogen detection) is widely criticized as outdated/ineffective; calls exist to replace it. Supply chain resilience improved but is not fully domestic or diversified.[7]

•Workforce, trust, and equity: Public health workforce faces shortages, burnout, and high departure rates. Trust eroded by politicization, mixed messaging, and misinformation during COVID, complicating future compliance (e.g., vaccination, masking). Health disparities (racial/ethnic, rural/urban, socioeconomic) amplified COVID impacts and remain risks. Community engagement and equity need strengthening.[8]

•Expert and commission assessments: The Bipartisan Commission on Biodefense’s 2024 National Blueprint states the nation “remains dangerously vulnerable,” calls for “immediate action,” and offers 36 recommendations/185 action items (stronger White House leadership via National Security Advisor role, quadrennial reviews, indoor air quality R&D, better detection, sustained MCM investment). Stimson Center, NEJM commentaries, and others note under-preparation, especially for H5N1-like threats or worse pathogens, with revisionism risking repeated mistakes. Global views (e.g., GPMB) highlight ongoing world vulnerability despite better capacities.[1]

Broader Context and Outlook

COVID exposed pre-existing weaknesses (despite high 2019 Global Health Security Index ranking): fragmented data, testing bottlenecks, supply shortages, inadequate surge capacity, and coordination failures. The US had high absolute deaths and per-capita impacts among high-income peers in key periods. Recent threats like H5N1 (widespread in animals, limited human cases so far) and mpox tested systems with mixed results—better tools but coordination/funding strains.[7]

Preparedness is not binary. The US has advanced scientific/medical capabilities, manufacturing potential, and stockpiles that position it better for rapid MCM deployment than in 2020. However, a severe, highly transmissible novel pathogen (or concurrent crises) could still overwhelm systems due to infrastructure underinvestment, political factors, trust deficits, and uneven subnational readiness. Sustained bipartisan funding, clearer authorities, workforce rebuilding, modernized detection/surveillance, supply chain resilience, and trust-building are repeatedly recommended as essential. Continuity across administrations and addressing fragmentation remain critical risks.

In short, the US is more prepared than pre-COVID but falls short of robust, resilient readiness for “the next big one.” Ongoing vigilance, investment, and implementation of existing recommendations would close many gaps.

Citations (8)

1biodefensecommission.orgNonprofits and think tanks
https://biodefensecommission.org/reports/the-national-blueprint-for-biodefense/
Backs: “Experts and bipartisan groups emphasize that biological threats (natural, accidental, or deliberate) are growing, and “immediate action” is still needed.”
2archives.govGovernment
https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2025/01/14/report-the-biden-harris-administration-roadmap-for-pandemic-preparedness-and-response/
Backs: “It has supported responses to H5N1, mpox, and other threats, with ongoing sustainment, quality assurance, and shelf-life extension efforts.”
3who.intGovernment
https://iris.who.int/bitstream/handle/10665/380155/9789240105409-eng.pdf?sequence=1sask
Backs: “It scores highly (often 4–5 out of 5 for demonstrated/sustainable capacity) in many technical areas such as immunization, laboratory systems, surveillance, health emergency management, and points of entry, though with recommendations for improvement.”
4gao.govGovernment
https://www.gao.gov/products/gao-24-107175
Backs: “Gaps in biodefense enterprise implementation of the National Biodefense Strategy persist.”
5tfah.orgNonprofits and think tanks
https://www.tfah.org/article/new-report-measures-states-preparedness-for-public-health-emergencies-including-infectious-disease-outbreaks-and-extreme-weather-events/
Backs: “Hospital and healthcare system surge capacity remains uneven.”
6tfah.orgNonprofits and think tanks
https://www.tfah.org/wp-content/uploads/2026/09/TFAH_Public_Health_Funding_2026_FNL.pdf
Backs: “Professional judgment budgets highlight multi-billion-dollar gaps for full MCM readiness against CBRN and emerging threats.”
7nejm.orgAcademic
https://www.nejm.org/doi/full/10.1056/NEJMp2406427
Backs: “Supply chain resilience improved but is not fully domestic or diversified.”
8who.intGovernment
https://www.who.int/publications/i/item/9789240105409
Backs: “Health disparities (racial/ethnic, rural/urban, socioeconomic) amplified COVID impacts and remain risks. Community engagement and equity need strengthening.”